These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34829213)

  • 1. The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience.
    Atoui A; Omeirat N; Fakhreddine O; El Alam R; Kanafani Z; Abou Dalle I; Bazarbachi A; El-Cheikh J; Kanj SS
    J Fungi (Basel); 2021 Oct; 7(11):. PubMed ID: 34829213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
    Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting.
    Ghafur A; Das B; Raja T; Easow J; Kartikeyan R; Easow BM; Ramanan SG
    South Asian J Cancer; 2024 Jul; 13(3):207-214. PubMed ID: 39410986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
    Cordonnier C; Rovira M; Maertens J; Olavarria E; Faucher C; Bilger K; Pigneux A; Cornely OA; Ullmann AJ; Bofarull RM; de la Cámara R; Weisser M; Liakopoulou E; Abecasis M; Heussel CP; Pineau M; Ljungman P; Einsele H; ;
    Haematologica; 2010 Oct; 95(10):1762-8. PubMed ID: 20634495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis for invasive fungal infection in pediatric patients with allogeneic hematopoietic stem cell transplantation.
    Perez P; Patiño J; Franco AA; Rosso F; Beltran E; Manzi E; Castro A; Estacio M; Valencia DM
    Blood Res; 2022 Mar; 57(1):34-40. PubMed ID: 35256547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
    Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
    Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.
    Linder KA; Kauffman CA; Patel TS; Fitzgerald LJ; Richards BJ; Miceli MH
    Transpl Infect Dis; 2021 Feb; 23(1):e13448. PubMed ID: 33448560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
    Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
    Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
    Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
    Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
    J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
    Herity LB; Cruz OA; Aziz MT
    J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.
    Mishra P; Agrawal N; Bhurani D; Agarwal NB
    Indian J Hematol Blood Transfus; 2020 Jan; 36(1):64-70. PubMed ID: 32174692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
    Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
    Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience.
    El-Ghammaz AMS; El-Zimaity M; Elafifi AM; Abdelwahed E; Moussa MM; Aboelmagd YA; Kotob MG; Fares HM
    Indian J Hematol Blood Transfus; 2020 Oct; 36(4):680-689. PubMed ID: 33100710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.